L. Lin et al., Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals Cyclin E as the best candidate gene for this amplicon, CANCER RES, 60(24), 2000, pp. 7021-7027
Genomic DNA amplification in tumors is frequently associated with an increa
sed gene copy number of oncogenes or other cancer-related genes. We have us
ed a two-dimensional whole-genome scanning technique to identify gene ampli
fication events in esophageal adenocarcinomas. A multicopy genomic fragment
from a tumor two-dimensional gel was cloned, and genomic amplification enc
ompassing this fragment was confirmed by Southern blot analysis. The corres
ponding DNA sequence was matched by BLAST to a BAC contig, which allowed th
e use of electronic-PCR to localize this amplicon to 19q12. Sequence tagged
site-amplification mapping, an approach recently implemented in our labora
tory (Lin, L. et al. Cancer Res., 60: 1341-1347, 2000), was used to charact
erize the amplicon, Genomic DNA from 65 esophageal and 11 gastric cardia ad
enocarcinomas were investigated for 19q12 amplification using quantitative
PCR at 11 sequence tagged site markers neighboring the cloned fragment. The
amplicon was narrowed from >8 cM to a minimal critical region spanning <0.
8 cM, between D19S919 and D19S882. This region includes the cyclin E gene.
Fourteen expressed sequence tags (ESTs) covering the minimal region were th
en assayed for potential gene overexpression using quantitative reverse tra
nscription-PCR. Seven of the selected ESTs were found to be both amplified
and overexpressed, Among these seven ESTs, cyclin E showed the highest freq
uency of gene amplification and overexpression In the tumors examined, whic
h allowed us to finalize the core-amplified region to <300 kb. These result
s indicate that cyclin E Is the likely target gene selected by the amplific
ation event at 19q12. The fact that cyclin E overexpression was found only
in the amplified tumors examined indicates that gene amplification underlie
s the cyclin E gene overexpression. Our study represents the first extensiv
e analysis of the 19q12 amplicon, and is the first to physically map the co
re-amplified domain to a region of <300 kb that includes cyclin E. Amplific
ation of 19q12 was found neither in the 28 esophageal squamous cancers nor
in the 39 lung adenocarcinomas examined but was observed in 13.8% of esopha
geal and 9.1% of gastric cardia adenocarcinomas.